Wen Chen Yeh
Chief Tech/Sci/R&D Officer chez Surrozen Operating, Inc.
Profil
Wen Chen Yeh is currently the Chief Scientific Officer at Surrozen Operating, Inc. He previously worked at Amgen, Inc. as a Scientific Executive Director from 2006 to 2016.
He also worked as a Professor at the University of Toronto.
In addition, he was the former Chief Scientific Officer at Surrozen, Inc. from 2016 to 2023.
Mr. Yeh holds a doctorate degree from The Johns Hopkins University and National Taiwan University.
Postes actifs de Wen Chen Yeh
| Sociétés | Poste | Début |
|---|---|---|
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01/05/2016 |
Anciens postes connus de Wen Chen Yeh
| Sociétés | Poste | Fin |
|---|---|---|
| SURROZEN, INC. | Chief Tech/Sci/R&D Officer | 31/07/2023 |
| AMGEN INC. | Chief Tech/Sci/R&D Officer | 01/04/2016 |
| University of Toronto | Corporate Officer/Principal | - |
Formation de Wen Chen Yeh
| The Johns Hopkins University | Doctorate Degree |
| National Taiwan University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AMGEN INC. | Health Technology |
| SURROZEN, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Surrozen Operating, Inc.
Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
